EMA Review of Daratumumab for the Treatment of Adult Patients with Multiple Myeloma.
Tzogani K et al. Oncologist. 2018 Jan 25. pii: theoncologist.2017-0328. doi: 10.1634/theoncologist.2017-0328. [Epub ahead of print].

Immunopathogenesis and immunotherapy of multiple myeloma.
Tamura H et al. Int J Hematol. 2018 Jan 24. doi: 10.1007/s12185-018-2405-7. [Epub ahead of print].

Survival of ethnic and racial minority patients with multiple myelomatreated with newer medications.
Pulte ED et al. Blood Adv. 2018 Jan 23;2(2):116-119. doi: 10.1182/bloodadvances.2017010512.

Trends in multiple myeloma presentation, management, cost of care, and outcomes in the Medicare population: A comprehensive look at racial disparities.
Ailawadhi S et al. Cancer. 2018 Jan 23. doi: 10.1002/cncr.31237. [Epub ahead of print].

Hematologists’ Preferences for First-line Therapy Characteristics for Multiple Myeloma in Japan: Attribute Rating and Discrete Choice Experiment.
Bolt T et al. Clin Ther. 2018 Jan 18. pii: S0149-2918(17)31118-9. doi: 10.1016/j.clinthera.2017.12.012. [Epub ahead of print].

Potential therapeutic and economic value of risk-stratified treatment as initial treatment of multiple myeloma in Europe.
Gaultney JG et al. Pharmacogenomics. 2018 Jan 15:0. doi: 10.2217/pgs-2017-0140. [Epub ahead of print].

Safety and efficacy of haploidentical stem cell transplantation for multiple myeloma.
Chen Y et al. Bone Marrow Transplant. 2018 Jan 12. doi: 10.1038/s41409-017-0069-1. [Epub ahead of print].

Freezing the graft is not necessary for autotransplants for plasma cell myeloma and lymphomas.
Kardduss-Urueta A et al. Bone Marrow Transplant. 2018 Jan 12. doi: 10.1038/s41409-017-0047-7. [Epub ahead of print].

Case Report of IgM Multiple Myeloma: Diagnosing a Rare Hematologic Entity.
Bonilla-Valentín FJ et al. Cancer Control. 2018 Jan-Mar;25(1):1073274817744448. doi: 10.1177/1073274817744448.

Multiple Myeloma: The Case of the Disappearing Band.
Mamone L et al. Lab Med. 2017 Dec 22;49(1):87-91. doi: 10.1093/labmed/lmx045.

Enhanced elimination of cyclophosphamide by high cut-off haemodialysis: single-dose pharmacokinetics in a patient with cast nephropathy.
Eden G et al. BMJ Case Rep. 2018 Jan 4;2018. pii: bcr-2017-221735. doi: 10.1136/bcr-2017-221735.

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018.
Kumar SK et al. J Natl Compr Canc Netw. 2018 Jan;16(1):11-20. doi: 10.6004/jnccn.2018.0002.

Amifostine reduces gastro-intestinal toxicity after autologous transplantation for multiple myeloma.
Malek E et al. Leuk Lymphoma. 2018 Jan 2:1-8. doi: 10.1080/10428194.2017.1408086. [Epub ahead of print].

Cost-effectiveness of Drugs to Treat Relapsed/Refractory Multiple Myeloma in the United States.
Carlson JJ et al. J Manag Care Spec Pharm. 2018 Jan;24(1):29-38. doi: 10.18553/jmcp.2018.24.1.29.

Analysis of long-term survival in multiple myeloma after first-line autologous stem cell transplantation: impact of clinical risk factors and sustained response.
Lehners N et al. Cancer Med. 2017 Dec 28. doi: 10.1002/cam4.1283. [Epub ahead of print].

A question of class: Treatment options for patients with relapsed and/or refractory multiple myeloma.
Cook G et al. Crit Rev Oncol Hematol. 2018 Jan;121:74-89. doi: 10.1016/j.critrevonc.2017.11.016. Epub 2017 Dec 5.

Healthcare resource utilization among patients with relapsed multiple myeloma in the UK, France, and Italy.
Gonzalez-McQuire S et al. J Med Econ. 2018 Jan 10:1-18. doi: 10.1080/13696998.2017.1421546. [Epub ahead of print].

Living with Relapsed Myeloma: Symptoms and Self-care Strategies.
Cormican O et al. J Clin Nurs. 2017 Dec 21. doi: 10.1111/jocn.14232. [Epub ahead of print].

The importance of the peripheral blood film in indicating a diagnosis of multiple myeloma with cryoglobulinaemia.
Hunt S et al. Br J Haematol. 2017 Dec 20. doi: 10.1111/bjh.15064. [Epub ahead of print].

Triplet vs. doublet drug regimens for managing multiple myeloma.
Offidani M et al. Expert Opin Pharmacother. 2017 Dec 21:1-13. doi: 10.1080/14656566.2017.1418856. [Epub ahead of print].

Upfront treatment of elderly myeloma patients: an overview and update.
Elsayed HG et al. Expert Rev Hematol. 2018 Jan 10:1-10. doi: 10.1080/17474086.2018.1419861. [Epub ahead of print].

Safety and efficacy of daratumumab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma.
Iida S et al. Int J Hematol. 2017 Dec 19. doi: 10.1007/s12185-017-2390-2. [Epub ahead of print].

Utility of a patient-reported outcome in measuring functional impairment during autologous stem cell transplant in patients with multiple myeloma.
Shah N et al. Qual Life Res. 2017 Dec 19. doi: 10.1007/s11136-017-1759-2. [Epub ahead of print].